Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Impact · against what's priced in

Kodiak Sciences is a strong buy following Phase 3 GLOW2 results that demonstrate high efficacy (62.5% improvement) and a clean safety profile. The acceleration of the BLA submission timeline significantly pulls forward the potential for commercialization and revenue.

KOD+0.80

No priced-in read yet

In context

The Phase 3 GLOW2 study showed a massive efficacy gap (62.5% vs 3.3% in sham) and an 85% reduction in sight-threatening complications, combined with an accelerated BLA submission timeline.

Read from the article alone

• healthcare▲20%
• biotech
• KOD
• bla
• clinical trials
• diabetic retinopathy
• drug development
• fda

Top 1 mover · tap to explore